Epilepsy. Parkinson’s. Crohn’s. Rheumatoid arthritis. Each condition used to carry with it a lengthy sentence of suffering. Today, UCB, a global biopharm company focused on severe diseases that is based in Brussels, Belgium, has developed therapies that mitigate many of the most debilitating aspects of those illnesses.
Of course, there is still much work to be done. UCB not only wants to find more answers, they want to find them quickly. That’s why they rely on Waters and a key Waters technology: Hydrogen Deuterium Exchange (HDX). It allows UCB scientists to better understand the binding of molecules to select proteins and therefore optimize molecules for future drugs. Most important, HDX is fast. It’s common to set up the experiment one day and have the data 24 hours later.
The right answers in a rapid timeframe allow UCB scientists to accelerate their work in turning today’s molecules into tomorrow’s medications.